CardioRenal is on a mission to save the lives of Chronic Kidney Disease and Heart Failure patients whose life is at risk because of blood potassium variations going unnoticed. The company’s device, TENOR, is undergoing a CE clinical trial and has been granted a « Breakthrough device label » by the FDA. As TENOR is connected to their web platform, remote physicians can change patient drug prescriptions to keep their patient’s blood levels within the safe range. The company is looking to close its series A within a few months to complete the submission to the FDA.